What is it about?
In this editorial I review the challenges of making a cytomegalovirus vaccine and place the publication of a trial using a CMV DNA vaccine in solid organ transplant recipients in context. The trial results were disappointing and reveal that vaccination against cytomegalovirus is not an easy nut to crack.
Featured Image
Why is it important?
Cytomegalovirus contributes to serious disease after transplantation due to the receipt of immunosuppressive drugs which weaken the immune system so that it cannot control the virus.
Perspectives
This publication tries to outline some of the reasons why vaccination against cytomegalovirus remains challenging and what we need to achieve to overcome these challenges.
Professor Vincent Emery
University of Surrey
Read the Original
This page is a summary of: Vaccination against cytomegalovirus: Still at base camp?, American Journal of Transplantation, June 2018, Wiley,
DOI: 10.1111/ajt.14969.
You can read the full text:
Contributors
The following have contributed to this page
